Modality
Vaccine
MOA
Anti-Tau
Target
B7-H3
Pathway
JAK/STAT
Ovarian CaFabryADHD
Development Pipeline
Preclinical
~Apr 2017
→ ~Jul 2018
Phase 1
~Oct 2018
→ ~Jan 2020
Phase 2
Apr 2020
→ Apr 2026
Phase 2Current
NCT05199090
2,777 pts·Ovarian Ca
2020-04→2026-04·Not yet recruiting
2,777 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-04-183w awayPh3 Readout· Ovarian Ca
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P2/3
Not yet…
Catalysts
Ph3 Readout
2026-04-18 · 3w away
Ovarian Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05199090 | Phase 2/3 | Ovarian Ca | Not yet recr... | 2777 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 |